Clinical efficacy and tolerability of olmesartan

Clinical Therapeutics

Volumn 26, Issue SUPPL. A, 2004, Pages

  Brunner, Hans R ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiotensin II receptor antagonist; Efficacy; Hypertension; Olmesartan medoxomil; Safety; Sartan; Tolerability

Indexed keywords

HYDROCHLOROTHIAZIDE; OLMESARTAN;

ADULT; AGED; ARTHRALGIA; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; INJURY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS; SINUSITIS; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION;

EID: 2342518792     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90143-9     Document Type: Article

References (5)

1. Brunner HR, Nussberger J. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. J Hypertens Suppl 2001;19(Suppl 1):S15-S20.
2. Püchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl 2001;19(Suppl 1):S41-S48.
3. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension [published correction appears in J Clin Hypertens (Greenwich). 2001;3:395]. J Clin Hypertens (Greenwich). 2001;3:283-291, 318.
4. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens. 2002;16(Suppl 2):S24-S28.
5. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762.